# Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)

> **NCT00105976** · PHASE2 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 260 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MM-093

## Key facts

- **NCT ID:** NCT00105976
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 260 (—)
- **Last updated:** 2008-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105976, "Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00105976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*